FORM 8.1(a) & (b) (Opening Position Disclosure)

Rhea-AI Summary

Alkermes (Nasdaq: ALKS) filed an Opening Position Disclosure (Form 8.1(a)&(b)) under Irish Takeover Panel rules on 5 November 2025 with a position date of 3 November 2025. The form names Avadel Pharmaceuticals plc as the related offeror/offeree and states Alkermes as the offeror. The disclosure reports no indemnities, option arrangements, or derivative agreements and no supplemental Form 8 attached. It lists J.P. Morgan staff holdings totalling 13,553 ordinary shares (0.0139%) in Avadel, split between two entities (53 and 13,500 shares).

DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS):

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE

1.     KEY INFORMATION

(a)	Full name of discloser:	Alkermes plc
(b)	Owner or controller of interests and short positions disclosed, if different from 1(a):   The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.	N/A
(c)	Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree	Avadel Pharmaceuticals  plc
(d)	Is the discloser the offeror or the offeree?	OFFEROR
(e)	Date position held:   The latest practicable date prior to the disclosure	3 November 2025
(f)	In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?   If it is a cash offer or possible cash offer, state "N/A"	N/A

2.     INTERESTS AND SHORT POSITIONS

If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates (Note 1)

N/A

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.     INTERESTS AND SHORT POSITIONS OF PERSONS ACTING
        IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE

Details of any interests and short positions (including directors' and other employee options) of any person acting in concert with the party making the disclosure:
Interests of J.P. Morgan (together with its members of staff under Rule  3.3(b)(v) of Part A of the Irish Takeover Rules), financial advisors to Alkermes plc, but, for clarity, not held on behalf of Alkermes plc:
	Party	Class of  Relevant Security	Number of  ordinary shares held at midnight (ET) on 3 November 2025	Percentage  of total issued share capital (rounded)
	55I, LLC	Ordinary  shares of US$0.01 each	53	0.0001 %
	JPMorgan Chase Bank, National Association	Ordinary  shares of US$0.01 each	13,500	0.0139 %
	TOTAL		13,553	0.0139 %
Details of any open stock-settled derivative positions (including traded  options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

Ap11

4.     OTHER INFORMATION

(a)    Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered  into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b)      Agreements, arrangements or understandings 
          relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

(c)     Attachments

Is a Supplemental Form 8 attached?	YES/NO
	No
Date of disclosure:	5 November 2025
Contact name:	Sandy Coombs, Alkermes
Telephone number:	+1 781 609 6377
Public disclosures under Rule 8.1 of the Rules must be made to a  Regulatory Information Service.

Ap12

NOTES ON FORM 8.1(a) and (b)

1.      See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) of Part B of the Rules.
   
   
2.      See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.
   
   
3.      If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
   
   For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
   
   References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/form-8-1a--b-opening-position-disclosure-302604930.html

SOURCE Alkermes plc

FAQ

What did Alkermes (ALKS) disclose in the Form 8.1(a)&(b) on November 5, 2025?

Alkermes disclosed an opening position under Irish Takeover Panel rules dated 3 Nov 2025, named Avadel Pharmaceuticals as the related party, and reported no indemnities or derivative arrangements.

How large were the J.P. Morgan staff holdings reported in Alkermes' November 5, 2025 disclosure?

The filing shows 13,553 ordinary shares held by J.P. Morgan staff, representing 0.0139% of issued share capital.

Does the Alkermes Form 8.1(a)&(b) include any option or derivative agreements affecting Avadel shares?

No. The disclosure states none for agreements, arrangements or understandings relating to options or derivatives.

Is there a Supplemental Form 8 attached to Alkermes' opening position disclosure for Avadel?

No. The filing indicates No supplemental Form 8 was attached.

Who is the contact listed on the Alkermes opening position disclosure filed November 5, 2025?

The contact is listed as Sandy Coombs, Alkermes with telephone +1 781 609 6377.